The FDA this week approved the first new Alzheimer’s treatment in nearly 20 years. But it almost didn’t make it to market. WSJ’s Joseph Walker untangles the complex story behind the drug Aduhelm and why its approval is raising questions.
To listen to this podcast episode, click on the Play button in the bar at the bottom of the screen. To listen while browsing, click on the Expand button at the bottom right to launch the player in a new browser tab/window.